Training OPportunites in Translational Imaging Education and Research (TOP-TIER)

项目总结 顶层(转译影像教育和研究的培训机会)是临床科学家 圣路易斯华盛顿大学博士后培训计划的目的是 为学员提供严格的翻译成像研究方面的指导。目标是 是让住院医生和其他受训人员为成为成功的独立调查员做好准备，并 最终成为各自领域的领导者，开发成像技术和应用程序，从而 人类受试者和影响医疗保健。精准医学是一种治疗疾病和 考虑到个体在基因、环境和生活方式上的差异的预防。发展 指导和监测患者特定治疗的患者特定生物标志物成像方法的方法将是 需要推动精密医学的发展。此外，训练有素的劳动力是利用新技术的关键 机器学习和人工智能的发展，可以跨学科应用，以 包括靶向分子成像、光声学和磁共振成像(MRI) 数据采集、图像处理和诊断。这种成像技术的进步是跨学科的 跨越物理、生物和数据科学的技术创新。这些研究始于 在动物疾病模型中使用基于病理学的靶向成像的临床前机制调查，以及 然后扩展到人类受试者。人体研究包括安全测试和食品和药物 美国食品和药物管理局(FDA)的新药研究(IND)和设备豁免(IDE)程序。终极的 目标是将研究创新广泛地提供给公众和整个执业医学 社区。尽管这种从板凳到床边的过程广受好评，但仍有一种 医学影像研究界关于如何开展临床前研究的知识差距 人类，以及如何将这些创新带给公众。此外，临床科学家-住院医生和 研究员-通常缺乏对驾驭研究法规要求以及 了解或执行将为创新机制提供信息的临床前研究的知识库。 在此次T32续订中，我们优化了培训，以提供支持性指导团队并涵盖技术 进展、研究的严谨性和拨款提交的实际方面，以更好地为未来的成像做准备 科学家为执行影响医疗保健的科学所面临的挑战。

PROJECT SUMMARY TOP-TIER (Training OPportunities in Translational Imaging Education and Research) is a clinician scientist post-doctoral training program at Washington University (WU) in St. Louis designed with the purpose of providing trainees with instruction in the performance of rigorous translational imaging research. The goal is to prepare resident and fellow trainees for careers as successful independent investigators and to ultimately become leaders in their field, developing imaging techniques and applications that translate into human subjects and impact healthcare. Precision Medicine is an approach to disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle. Development of methods of patient-specific biomarker imaging to guide and monitor patient-specific therapies will be needed to advance Precision Medicine. Moreover, a trained workforce is key to taking advantage of new developments in machine learning and artificial intelligence which can be applied across disciplines, to include targeted molecular imaging, photoacoustics, and magnetic resonance imaging (MRI) in terms of data acquisition, image processing, and diagnosis. Such imaging advances are interdisciplinary with technology innovations crossing the physical, biological, and data sciences. These studies start with preclinical mechanistic inquiries using targeted pathology-based imaging in animal disease models, and then expand into human subjects. Human studies include safety testing and the Food and Drug Administration’s (FDA) Investigational New Drug (IND) and Device Exemption (IDE) process. The ultimate goal is to make research innovations widely available to the public and the entire practicing medical community. Although this “bench-to-bedside” process has been widely acclaimed, there remains a knowledge gap in the medical imaging research community as to how to take preclinical research into humans, and how to then take these innovations to the public. Moreover, clinical scientists – residents and fellows – often lack the understanding to navigate research regulatory requirements as well as the knowledge base to understand or perform preclinical research that will inform the mechanism of innovation. In this T32 renewal, we have optimized training to provide supportive Mentoring Teams and cover technical advances, research rigor, and the practical aspects of grant submission to better prepare future imaging scientists for the challenges of performing science which impacts healthcare.